DiagnaMed Holdings Corp. announced the launch of Health GenAI, a new division focused on the development and commercialization of a suite of generative AI ready-made and customizable applications powered by GPT-4 to support the healthcare market in improving patient outcomes, operational workflow and efficiency. The Company expects to launch at least three products from its Health GenAI division this year.

As part of its Health GenAI division, the Company recently announced the launch of its first commercial product, FormGPT.io (www.FormGPT.io), a generative AI data collection and analysis solution for the healthcare market, which was born from the development experience and features of CERVAI™. FormGPT.io allows licensed medical professionals, hospitals, and life science to create customized forms and surveys with the support of ChatGPT and collect relevant patient data, obtain pre-and-post-visit and treatment feedback, monitor patient progress, and analyze results for decision-making. FormGPT.io empowers licensed professionals and clinical researchers to easily and quickly develop forms and surveys that complement their workflow and specific patient and research objectives.

In addition, FormGPT.io aims to improve user services, workflow, patient outcomes and engagement. The Company is making its minimal viable product version of FormGPT.io available to the public with a 7-day free trial.